Biotechnology Drug DevelopmentBoston, MA
Asymmetrex is a private, for-profit biotechnology company that specializes in technologies for stem cell medicine. Prior to 2015, Asymmetrex was known as The Adult Stem Cell Technology Center. Asymmetrex's founder and director is a leading authority on the unique properties of adult tissue stem cells. Asymmetrex holds a rich portfolio of intellectual property for technologies that address major barriers to success in regenerative medicine. These include patented methods for producing adult tissue stem cells and their differentiated derivatives in trillion-cell quantities; counting adult tissue stem cells; engineering adult tissues stem cells; and evaluating effects of new drug candidates on adult tissue stem cells. Currently, Asymmetrex is conducting a one year crowdsourcing campaign to evaluate the range of applications for the company's H2A.Z asymmetry biomarker for counting tissue stem cells. Scheduled to run from April 2015 to May 2016, the campaign is designed to determine in how many different mammalian species and different tissues H2A.Z asymmetry can be used to identify and quantify resident tissue stem cells. For more information visit: http://crowdsourcing.asymmetrex.com Current products include renewable adult tissue stem cells strains (e.g., human liver, pancreas), tissue stem cell-specific biomarkers with sufficient specificity for counting tissue stem cells for the first time, and exclusive licensing of technologies for specific fields of use. Asymmetrex is currently pursuing two new commercialization targets. The lead target is pursued with strategic partner AlphaSTAR Corp. The companies have teamed up to develop a new technology for identifying pharmaceutical drug candidates that are toxic to tissue stem cells. The new AlphaSTEM technology has the potential to save drug companies hundreds of millions of dollars in presently wasted drug development costs, reduce the time to market for safe and effective drugs, and reduce the frequency of adverse drug events for clinical trial participants and future patients. Independently, Asymmetrex is currently developing a commercialization plan to establish a biomanufacturing process for large scale production of human liver stem cells and derivative hepatocyte-differentiated cells for use in transplantation therapies for liver failure and drug evaluations, respectively.